SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

被引：0
|
作者：
Javier Escalada
机构：
[1] Clínica Universidad de Navarra,Department of Endocrinology and Nutrition
[2] Instituto de Salud Carlos III,CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
来源：
Diabetes Therapy | 2022年 / 13卷
关键词：
Type 2 diabetes; SGLT2 inhibitors; Cardiorenal; Cardiovascular disease; Kidney disease; Heart failure; Morbidity; Mortality; Chronic kidney disease; Cardiorenal continuum;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 3
页数：2
相关论文
共 50 条
  • [41] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [42] Ketoacidosis with SGLT2 Inhibitors
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1471): : 94 - 94
  • [43] SGLT2i Treatment Reduces Cardiorenal Disease Risk in T2D Patients Without Established Cardiovascular and Renal Diseases: A Large Observational Study
    Komuro, Issei
    Bodegard, Johan
    Thuresson, Marcus
    Yajima, Toshitaka
    Eriksson, Jan W.
    Norhammar, Anna
    Birkeland, Kare I.
    Kadowaki, Takashi
    CIRCULATION, 2019, 140 (25) : E980 - E980
  • [44] SGLT2 inhibitors and cardioprotection
    Chen, S.
    Wang, Q.
    Christodoulou, A.
    Mylonos, N.
    Bakker, D.
    Wakker, V.
    Hollmann, M. W.
    Weber, N. C.
    Coronel, R.
    Christoffels, V.
    Andreadou, I.
    Zuurbier, C. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [45] Finerenone in Patients with CKD and T2D by SGLT-2i Treatment: An Analysis of the FIDELIODKD Study
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Chan, Juliana
    Kooy, Adriaan
    McCafferty, Kieran
    Schernthaner, Guntram
    Wanne, Christoph
    AMERICAN HEART JOURNAL, 2021, 242 : 160 - 161
  • [46] SGLT2 inhibitors: are they safe?
    Filippas-Ntekouan, Sebastian
    Filippatos, Theodosios D.
    Elisaf, Moses S.
    POSTGRADUATE MEDICINE, 2018, 130 (01) : 72 - 82
  • [47] Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Gonzalez-Albarran, Olga
    Morales, Cristobal
    Perez-Maraver, Manuel
    Juan Aparicio-Sanchez, Jose
    Simo, Rafael
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 35 - 49
  • [48] Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Olga González-Albarrán
    Cristóbal Morales
    Manuel Pérez-Maraver
    José Juan Aparicio-Sánchez
    Rafael Simó
    Diabetes Therapy, 2022, 13 : 35 - 49
  • [49] SGLT2i Use and the Risk of Nephrolithiasis in Patients with T2D
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary
    Mastrorilli, Julianna M.
    Wexler, Deborah J.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [50] The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
    Brown, Emily
    Wilding, John P. H.
    Alam, Uazman
    Barber, Thomas M.
    Karalliedde, Janaka
    Cuthbertson, Daniel J.
    ANNALS OF MEDICINE, 2021, 53 (01) : 2072 - 2089
12345